No Data
No Data
IGM Biosciences Faces Uncertainty Amid Cash Preservation and Restructuring Efforts
Morgan Stanley Sticks to Their Sell Rating for IGM Biosciences (IGMS)
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), Aziyo Biologics (ELUT) and IGM Biosciences (IGMS)
RBC Capital Downgrades IGM Biosciences(IGMS.US) to Hold Rating, Cuts Target Price to $1.5
Stifel Downgrades IGM Biosciences(IGMS.US) to Hold Rating, Cuts Target Price to $2.5
Analysts Offer Insights on Healthcare Companies: Mind Medicine (MNMD), IGM Biosciences (IGMS) and ALX Oncology Holdings (ALXO)